Clinical Data Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 BioSpaceSales of Amgen's thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.Clinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) BioSpace Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025. Clinical DataOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Amgen scores with new thyroid eye disease formulationNext: AI giant Anthropic buys Coefficient Bio for $400m Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
